Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes
Growth Hormone therapy has been shown to induce transient insulin resistance in children, and there is concern regarding the diabetogenic potential of GH therapy in children born small for gestational age (SGA). In this case, female patient born SGA with a weight of 2,750 g (−1.73 standard deviation...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | Case Reports in Pediatrics |
| Online Access: | http://dx.doi.org/10.1155/2023/9912817 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832553073101242368 |
|---|---|
| author | Naohiro Nomura Yuko Tanabe Miki Minami Junji Takaya Kazunari Kaneko |
| author_facet | Naohiro Nomura Yuko Tanabe Miki Minami Junji Takaya Kazunari Kaneko |
| author_sort | Naohiro Nomura |
| collection | DOAJ |
| description | Growth Hormone therapy has been shown to induce transient insulin resistance in children, and there is concern regarding the diabetogenic potential of GH therapy in children born small for gestational age (SGA). In this case, female patient born SGA with a weight of 2,750 g (−1.73 standard deviation (SD)) and length of 45.5 cm (−2.6 SD). The patient’s father and paternal grandfather were diagnosed with type 2 diabetes mellitus. At 3 years of age, the patient presented with short stature; height and weight were 85 cm (−2.5 SD) and 13 kg (−0.19 SD), respectively. She was placed on GH therapy. At 11 years of age, her fasting blood glucose and hemoglobin A1c levels were 116 mg/dL and 7.4%, respectively. Blood test results were negative for anti-glutamic acid decarboxylase and anti-islet antigen-2 antibodies. The patient discontinued GH therapy and started diet therapy and oral metformin (500 mg/day) administration. Five months later, the hemoglobin A1c level was 5.3% and glycemic control further improved. To our knowledge, family history may be an important risk factor for GH-induced diabetes. So, the GH dosage for patients born SGA with family history of diabetes should be adjusted so as not to be too excessive, and long-term follow-up studies will be required to evaluate fully the effects of GH therapy for them. |
| format | Article |
| id | doaj-art-94c09034d9a1452e991c3b0095141821 |
| institution | Kabale University |
| issn | 2090-6811 |
| language | English |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Pediatrics |
| spelling | doaj-art-94c09034d9a1452e991c3b00951418212025-02-03T05:57:02ZengWileyCase Reports in Pediatrics2090-68112023-01-01202310.1155/2023/9912817Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 DiabetesNaohiro Nomura0Yuko Tanabe1Miki Minami2Junji Takaya3Kazunari Kaneko4Department of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsDepartment of PediatricsGrowth Hormone therapy has been shown to induce transient insulin resistance in children, and there is concern regarding the diabetogenic potential of GH therapy in children born small for gestational age (SGA). In this case, female patient born SGA with a weight of 2,750 g (−1.73 standard deviation (SD)) and length of 45.5 cm (−2.6 SD). The patient’s father and paternal grandfather were diagnosed with type 2 diabetes mellitus. At 3 years of age, the patient presented with short stature; height and weight were 85 cm (−2.5 SD) and 13 kg (−0.19 SD), respectively. She was placed on GH therapy. At 11 years of age, her fasting blood glucose and hemoglobin A1c levels were 116 mg/dL and 7.4%, respectively. Blood test results were negative for anti-glutamic acid decarboxylase and anti-islet antigen-2 antibodies. The patient discontinued GH therapy and started diet therapy and oral metformin (500 mg/day) administration. Five months later, the hemoglobin A1c level was 5.3% and glycemic control further improved. To our knowledge, family history may be an important risk factor for GH-induced diabetes. So, the GH dosage for patients born SGA with family history of diabetes should be adjusted so as not to be too excessive, and long-term follow-up studies will be required to evaluate fully the effects of GH therapy for them.http://dx.doi.org/10.1155/2023/9912817 |
| spellingShingle | Naohiro Nomura Yuko Tanabe Miki Minami Junji Takaya Kazunari Kaneko Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes Case Reports in Pediatrics |
| title | Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes |
| title_full | Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes |
| title_fullStr | Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes |
| title_full_unstemmed | Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes |
| title_short | Growth Hormone Therapy for Small for Gestational Age Short Stature Develops Type 2 Diabetes |
| title_sort | growth hormone therapy for small for gestational age short stature develops type 2 diabetes |
| url | http://dx.doi.org/10.1155/2023/9912817 |
| work_keys_str_mv | AT naohironomura growthhormonetherapyforsmallforgestationalageshortstaturedevelopstype2diabetes AT yukotanabe growthhormonetherapyforsmallforgestationalageshortstaturedevelopstype2diabetes AT mikiminami growthhormonetherapyforsmallforgestationalageshortstaturedevelopstype2diabetes AT junjitakaya growthhormonetherapyforsmallforgestationalageshortstaturedevelopstype2diabetes AT kazunarikaneko growthhormonetherapyforsmallforgestationalageshortstaturedevelopstype2diabetes |